Article

The future promise of advanced therapies in ophthalmology

Six years after the first approved gene therapy in ophthalmology, the field is seeing a flurry of activity in innovative cell and gene therapy (CGT) studies addressing high unmet needs. Here’s what could be in store for the future.


Louis Cicchini
Director, Scientific Affairs, Cell & Gene Therapy at Cencora

Fill out the form below to read more

Pardot Form

Related resources

Article

ISPOR 2026: perspectives shaping the future of access, evidence, and patient impact
Learn more

Product overview

Introducing FormularyDecisions PIE Market Insights
Learn more

Article

When worlds converge: How Most-Favored-Nation policy and International Reference Pricing reshape global market access interdependencies
Learn more

Connect with our cell and gene experts

Schedule some time with our cell and gene experts today. We look forward to hearing from you.
Abstract